Julie Gavin, MD
Obstetrics · Buffalo, NYNPI 1700083276
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $733 of the $842 with a category attached, or 87.1%. 15 manufacturers reported payments, led by Mayne Pharma Commercial LLC at 35.6% of the total. Reporting peaked in 2023 at $233 and has fallen 93.0% since, to $16 in 2025.
Across 38 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mayne Pharma Commercial LLC$300
- Astellas Pharma US Inc$90
- Pfizer$81
- AbbVie$67
- Mckesson Patient Care Solutions Inc.$61
- Therapeuticsmd, Inc.$40
- plus $203 from 9 others
What the payments were for
- Food & beverage$73387%
- Education$10813%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mayne Pharma Commercial LLC | 10 | $300 |
| Astellas Pharma US Inc | 1 | $90 |
| Pfizer | 5 | $81 |
| AbbVie(2 entities) | 5 | $67 |
| Mckesson Patient Care Solutions Inc. | 2 | $61 |
| Therapeuticsmd, Inc. | 3 | $40 |
| Novo Nordisk | 2 | $36 |
| Alfasigma USA, Inc. | 2 | $32 |
| Daiichi Sankyo Inc. | 2 | $26 |
| Exact Sciences | 1 | $25 |
| Gilead | 1 | $22 |
| Scynexis, Inc. | 1 | $19 |
| AMAG Pharmaceuticals, Inc. | 1 | $18 |
| Avion Pharmaceuticals | 1 | $13 |
| Exeltis, USA Inc. | 1 | $11 |
How this compares
$842 in reported general payments places this provider in the 75th percentile of 82 obstetrics providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OsphenaOspemifene | 12 | $5,698 |
| Estradiol | 22 | $2,590 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 11 | $332 |
| ValacyclovirValacyclovir Hcl | 11 | $268 |
| Fluconazole | 22 | $68 |
| Ciprofloxacin Hcl | 11 | $52 |
Paid to pharmacies, not to this prescriber.
Other obstetrics in Buffalo
- Judine DavisBuffalo$1K
- Arthur JonesMiddletown$13K
- Anna BarbieriNew York$9K
- Mitchell KramerHuntington Station$6K
- Albert AyoubBrooklyn$4K
- Shahnoz RustamovaNew York$4K
- Suzanne LajoieNew York$3K
- Lorranie WilliamsCambria Heights$2K
- Carol LopesSyracuse$2K
- Danielle RooneyLatham$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.